The Program Committee for the IASLC 2022 World Conference on Lung Cancer thanks you for your submission of scientific abstracts.
|Call for Abstract||Submission Closed|
Abstract Submission Deadline
(includes Late-Breaking Abstract placeholders)
|March 16, 2022 (23:59 PST)|
|Education Awards Application Deadline||March 16, 2022 (23:59 PST)|
|Notification of Abstract Acceptance||April 27, 2022|
|Notification of Education Awards||April 27, 2022|
|Late-Breaking Abstract Final Date Due||May 27, 2022 (23:59 PST)|
|Presenting Author Registration Deadline||June 10, 2022|
|Late-Breaking Abstract Notifications||June 20, 2022|
|Abstract Titles Release Date||June 24, 2022|
|Presentation Slides Submission Deadline||July 5, 2022 (23:59 PST)|
|Full Abstract Release Date @ 18:00 EST (Except for Embargoed Abstracts)||July 12, 2022|
|ePoster Submission Deadline||July 27, 2022 (23:59 PST)|
|Tobacco Control and Risk Reduction||-||Tobacco Control Policy, Tobacco Prevention Patient, Framework Convention on Tobacco Control, Smoking Cessation, Radon, Bio Mass, Environmental|
|Early Detection and Screening||-||Screening, Early Detection, Low Dose Spiral CT Scan, Early Diagnosis, Exhaled Air, Pulmonary Nodule, GGO, Biomarkers For Early Detection, Risk Models, Nodule Evaluation, Artificial Intelligence For Early Detection, Radiomics|
|Tumor Biology and Biomarkers||-||Tumor Biology, Mouse Models, Basic Science, Translational Science, Bioinformatics, Transcriptomics and Other Novel Omics|
|Pathology||-||Tumor Microenvironment, IHC, FISH, NGS, Tissue Diagnostics, Novel Tumor|
|Pulmonology, Radiology, and Staging||-||Staging, Tumor Size Characteristics, Node Characteristics, Metastatic Characteristics, IASLC Staging System|
|Early Stage Non-small Cell Lung Cancer||Surgery||Neoadjuvant/ Adjuvant therapies, Early Stage, Minimally Invasive Surgery, Stage I, Stage II, Stereotactic Body Radiation Therapy, Protons, Guidelines, Salvage Therapy, Radiological Changes, PFT, Radiobiology|
|Radiotherapy and Other Ablative Techniques|
|Neoadjuvant and Adjuvant Systemic Therapy (Multi-modality treatment, Immunotherapy, Molecular Targeted Treatments)|
|Locally Advanced Non-small Cell Lung Cancer||Surgery||Chemoradiation, Immunotherapy, Surgical resection, Tri-modality Therapy, Neoadjuvant, Consolidation approach, PFT, SABR/SBRT, Protons/Carbon Ions, Chemoimmunotherapy, Postoperative Treatment, Guidelines, Radiobiology, Toxicity, Physics|
|Chemoradiotherapy and Radiotherapy|
|Neoadjuvant and Adjuvant Therapy|
|Metastatic Non-small Cell Lung Cancer||Palliative Chemotherapy||Stereotactic Body Radiotherapy, Local Ablative Therapy, Metastasectomy, Oligo-progression, Novel Cytotoxics, Phase I, Pre-clinical, Anti-body Conjugates, Toxicity, Tumor Micro-environment, Bi-specific Ab, Vaccine Therapy, Cellular Therapy, Chimeric Antigen Receptors, Viroimmunotherapy, Cytokine Therapy, Translational Research, Check-Point Blockade Beyond PD-1/L1, Phase II and III Clinical Trials, Immune Checkpoint Inhibitors, Randomised Controlled Trials, Biomarkers, Circulating Tumor Cells, Circulating Tumor DNA, Cell Free DNA, Circulating Cell-Free Noncoding RNAs, Circulating Exosomes, Liquid Biopsy, Pleural Effusion Assays, Urine Based Testing, SABR, Oligorecurrence, Abscopal Effect, Hippocampus Preservation, Reirradiation, Combined Approach, Chemoradiation, Radioimmunotherapy, SRS, Radiosurgery, Guidelines, Radiobiology|
|Molecular Targeted Treatments|
|Small Cell Lung Cancer and Neuro-endocrine Tumors||-||Small Cell Lung Cancer, Neuroendocrine Tumors, Atypical Carcinoid|
|Mesothelioma, Thymoma, and Other Thoracic Malignancies||-||Malignant Mesothelioma, Thymoma, Thymic Carcinoma, Thymic Epithelial Tumors, Esophageal Cancer|
|Palliative and Supportive Care||-||Palliative Care, Decision-making, Decision Support Techniques, Ethics, Quality of Life, Integrative care|
|Nursing and Allied Health Professionals||-||Rehabilitation, Physiotherapy, Survivorship Care|
|Patient Advocacy||-||Survivorship, Advocacy, Community Outreach, Patient-driven Research, Advocacy Foundations, Patient Advocacy, Patient Reported Outcomes, Lung Cancer Stigma|
|Management of Lung Cancer in the Era of COVID-19||-||Impact on Care, Complications, Risk Factors, Impact on Diagnosis and Treatment|
|Global Health, Health Services Research, and Health Economics||-||Patterns of care, Lower Socioeconomic Countries Global Health, Health Policy, Cost Effectiveness, Quality of Care, Healthcare Access, Qualitative Research, Real-World Data, Observational Cohort Studies, Disease Registries And Databases, Artificial Intelligence, Machine Learning|
Definition: Original scientific research that summarizes work done and major research findings.
Required sections for abstract submission:
Clinical Trials in Progress (eligible for designation as e-poster only)
Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.
Case Report (eligible for designation as e-poster only)
Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient.
Required sections for abstract submission:
Late-Breaking Abstract (LBA) Submission
Definition: LBA designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission due to study timelines.
LBA designation is not a means for extending the regular abstract deadline. Any abstract that fails to meet LBA requirements will be designated as a regular abstract and rated based on the information available on the submission deadline.
Submission requirements: Authors of LBA must submit a place holder abstract through the abstract portal by March 16, 2022 (23:59 PST).
Required sections for place holder abstracts:
Review: The Scientific Program Committee will review LBA abstract placeholder applications. Authors of approved LBAs will be notified and instructed on deadlines and the processes for submitting final data by May 27, 2022, the final LBA deadline. LBA abstracts not completed by the May 27, 2022 deadline will be automatically withdrawn and will not be considered for the meeting.
|Word Limit:||500 words (does not include title and authors)
Abstracts should be organized in different sections based on the selected abstract type. Please refer to the 'Abstract Type' section on this page for further information.
|Title Word Limit:||125 characters total (including spaces)|
|Tables:||No limit; each table counts as 100 words|
|Images:||2 maximum; each image counts as 100 words|
|Format(s):||Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is acceptable and preferred.|
|Fee:||No submission fee|
|Submission Limit:||Presenters are limited to 2 oral presentations|
|Number of Co-authors:||No limit|
Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.
Financial disclosure and affiliation information is required for the presenting author. For reference, here is a link to the disclosure form.
Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline March 16, 2022.
For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370
When will the abstract titles be published online?
Abstract titles will be released June 24, 2022.
When will the full abstracts be published online?
The full abstract bodies will be released July 8, 2022, except for those abstracts included in the WCLC 2022 Press Program.
Does WCLC accept abstracts that have been submitted and presented to a previous Conference (ie, encore abstracts, trials in progress encore abstracts)?
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations in the introduction section of the abstract.
Are case reports/case series considered for presentations?
Yes, we do allow the submission of case reports.
What is the withdraw deadline for regular submissions and late breaking submissions?
The presenting author registration deadline is June 10, 2022. Abstract presentations for a presenter not registered by this date will be withdrawn from the program.
For late-breaking abstracts, does the Conference only permit abstracts that report on Phase 3 [and higher] studies?
Only clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission (March 16, 2022) due to study timelines will be granted late-breaking submission privileges. An abstract study does not need to be a Phase III clinical trial to be eligible for late-breaking data submission.
Could I send my manuscript to publish to a journal in my country before WCLC?
Submitters may submit their abstract to be published in a journal prior to the abstract being released in conjunction with WCLC, however, the Scientific Program Committee will be reviewing abstracts for novelty and impact on patient care, and a publication in a journal prior to the meeting may impact the scoring of the abstract.
Is industry allowed to be in lead or senior author positions on the author list for WCLC abstract submissions? Are there restrictions towards pharmaceutical/commercial authors on presenting abstracts at the meeting?
Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present e-poster presentations.
Would it be possible to submit an abstract without results and conclusion?
All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Report abstracts must be completed by the March 16, 2022 deadline. Any Regular Abstracts and Case Reports that are incomplete after the March 16, 2022 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the March 16, 2022 deadline without Results and Conclusions as those sections are optional for CTPS submissions. Late-breaking Abstract designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder (March 16, 2022) due to study timelines. To submit a late-breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the March 16, 2022 deadline.
Is there a limit on the number of abstracts in which an author can be lead author?
There is no limit to the number of abstracts in which an author can be lead author. An individual may not give more than two oral presentations.
Is there any charge for the submission of abstracts, and if so, how much is it?
No, there is no charge to submit an abstract to WCLC.
For inquiries, please contact wclc2022-abstracts at icsevents.com. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.
Keep up to date with Conference News & Alerts.